Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, expanding its portfolio into rare endocrine diseases with assets like PALSONIFY and atumelnant.
The acquisition signifies Vertex Pharmaceuticals' strategic move to diversify its drug pipeline into rare endocrine diseases, adding to a trend of major pharmaceutical companies acquiring promising therapies in specialized fields.
Vertex Pharmaceuticals has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash. The deal, which was unanimously approved by both companies' boards, is expected to close in the third quarter of 2026.
Crinetics brings to Vertex a portfolio of endocrinology assets, including its recently launched drug PALSONIFY (paltusotine) for acromegaly and its Phase 3 candidate atumelnant, an ACTH receptor antagonist for congenital adrenal hyperplasia (CAH). Vertex anticipates that the acquisition will expand its reach beyond its current focus areas into rare endocrine diseases.
Pick the topics you care about. Get only what matters, on your cadence.